Mir195 enables Ebf1-deficient hematopoietic progenitor cells to mature into B cells, suggesting some miRNA can substitute for transcription factors in differentiation.

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

The new version of CAR-T therapy has shown the ability to effectively destroy cancer cells in mice without suppressing the ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

Researchers developed a DNA-scaffolded vaccine that achieves the first step in generating a significant population of B cells that produce broadly neutralizing antibodies against HIV.

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...